ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma reported $5M in collaboration revenue for 3Q 2026, up from none a year earlier, driven by an ARR-002 license agreement. Net loss widened to $40.31M, or $0.81 per share, due to higher R&D and administrative costs. The company's Phase 3 trial for firmonertinib did not meet its primary endpoint.

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

Guggenheim kept a Buy rating on ArriVent BioPharma (AVBP) with a $30 price target, suggesting a 95.3% upside from the Oct 26 close. The firm cited promising early Phase 1 data for ARR-217 in metastatic colorectal cancer, raising its probability of success to 45%. Recent analyst price targets for AVBP range from $18 to $29.

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.

ArriVent BioPharma reported Phase 1 data for ARR-217, showing a 44.8% response rate at 6 mg/kg in pretreated colorectal cancer patients. The disease control rate was 93.1% at this dose. At 4 mg/kg and higher, the response rate was 34.2% with a 91.8% disease control rate. Grade 3 or higher adverse events occurred in 30.1% of patients. The company plans to advance to Phase 1b dose optimization.